health
April 19, 2026
Trump signs order to speed review of psychedelics, including the controversial drug ibogaine
Ibogaine is banned under the federal government's most restrictive category for illegal, high-risk drugs.
TL;DR
- President Trump ordered his administration to speed up reviews of certain psychedelic drugs, notably ibogaine.
- Ibogaine is classified as a high-risk, illegal drug but is showing promise for treating PTSD and opioid addiction.
- The executive order aims to accelerate research and treatment access for psychedelic drugs.
- The FDA will offer national priority vouchers for three psychedelics, allowing for faster approval, and is clearing the way for ibogaine human trials.
- Despite known cardiovascular risks, ibogaine has support from veteran groups and conservative lawmakers.
- The move could encourage other states to fund ibogaine research, following Texas's lead.
- Owners of ibogaine clinics acknowledge the federal acknowledgment but note no immediate change in insurance coverage or approval status.